Peficitinib hydrobromide (marketed as Smartflap) is an oral Janus kinase (JAK) inhibitor approved mainly in Japan and South Korea for treating moderate-to-severe rheumatoid arthritis (RA) in patients with inadequate responses to conventional therapies. It reduces joint pain and inflammation, and is used to treat adults, either as monotherapy or in combination with other DMARDs. It is grouped under the following drug class(es): Immunosuppressants. Its therapeutic use is listed as anti-inflammatories and antirheumatic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Smyraf (TN) and ASP015K hydrobromide. Its PubChem CID is 67998300.
Peficitinib hydrobromide
| CAS No | 1353219-05-2 |
|---|---|
| Molecular Formula | C18H23BrN4O2 |
| Molecular Weight | 407.3 g/mol |
| Synonyms | 4-[[(1S,3R)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide;hydrobromide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Peficitinib hydrobromide (marketed as Smartflap) is an oral Janus kinase (JAK) inhibitor approved mainly in Japan and South Korea for treating moderate-to-severe rheumatoid arthritis (RA) in patients with inadequate responses to conventional therapies.
The listed CAS number is 1353219-05-2.
The listed molecular formula is C18H23BrN4O2.
The listed molecular weight is 407.3 g/mol.
4-[[(1S,3R)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide;hydrobromide.
The source lists Smyraf (TN) and ASP015K hydrobromide.